+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors



Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors



Journal of Urology 161(4): 1148-1152



Purpose: We determine the efficacy and safety of 2 cycles of adjuvant chemotherapy after orchiectomy in patients with high risk clinical stage I nonseminomatous germ cell tumor of the testis as an alternative to retroperitoneal lymphadenectomy or watchful waiting. Materials and Methods: A total of 60 consecutive patients with clinical stage I nonseminomatous germ cell tumor of the testis and 1 or more risk factors were entered into this prospective study. Criteria for high risk were embryonal cell carcinoma, tumor invasion of blood or lymph vessels, or tumor stage pT2 or greater. Chemotherapy consisted of 2 cycles of cisplatin, vinblastine and bleomycin or bleomycin, etoposide and cisplatin. Results: Of the 60 patients 1 refused chemotherapy and 1 was lost to followup 1.5 years after treatment. The remaining 58 patients have been followed for a median of 93 months (range 32 to 146). World Health Organization grade 4 toxicity was observed in 9 of the 116 chemotherapy cycles, and consisted mainly of transient neutropenia and thrombocytopenia. No significant long-term sequelae were detected. There was 1 relapse after 22 months in a patient with adult teratoma in the ipsilateral region of the iliac vessels who remained disease-free 85 months after surgical excision of the lesion. Another patient had a seminoma in the contralateral testicle with interaortocaval lymph node metastases 7.5 years after adjuvant chemotherapy. The remaining 56 men are without relapse or contralateral tumor to date. Conclusions: We recommend adjuvant chemotherapy as an efficient therapeutic alternative to retroperitoneal lymphadenectomy for high risk nonseminomatous germ cell tumor of the testis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010936821

Download citation: RISBibTeXText

PMID: 10081858

DOI: 10.1016/s0022-5347(01)61615-x


Related references

Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. Journal of Clinical Oncology 14(2): 441-448, 1996

Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. Journal of Urology 179(1): 163-166, 2008

Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy. Annals of Oncology 26(2): 374-377, 2015

Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: Selection criteria and long-term results. Mayo Clinic Proceedings 70(9): 821-828, 1995

Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Annals of Oncology 21(9): 1858-1863, 2010

Adjuvant chemotherapy in patients with high risk stage i nonseminomatous germ cell tumors. Journal of Urology 147(4 Suppl.): 335A, 1992

Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. European Urology 58(6): 912-918, 2010

Long-term results following one course of adjuvant chemotherapy for high-risk stage I non-seminomatous germ cell tumors The Spanish germ cell cancer group experience. EJC Suppl.s 1(5): S266, 2003

Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Journal of Clinical Oncology 21(8): 1505-1512, 2003

Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. Urologic Oncology 29(2): 189-193, 2011

Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Medical Oncology 30(1): 494, 2013

Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors. World Journal of Urology 35(7): 1103-1110, 2017

Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumor. Journal of Urology 163(6): 1785-1787, 2000

Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. European Urology 46(2): 209, 2004

Mp10-09 Fifteen Years After Treatment With One Adjuvant Cycle Of Etoposide, Bleomycin And Cisplatin Chemotherapy Outcomes In Patients With High Risk Nonseminomatous Germ Cell Tumors Clinical Stage I. Extended Follow Up Of A Prospective Single Arm Clinical Trial Cohort. The Journal of Urology 191(4): e117-e118, 2014